5000 Background: The availability of new agents for men with CRPC, recognition of new
disease phenotypes, and an evolving regulatory environment have created the need for new …

Introduction Although PSA screening has been rationalized, prostate cancer continues to
have the highest incidence rate in 2021, and alone accounts for 26% of cancer diagnoses in …

Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …

Prostate cancer is the second most common cause of cancer-related death in men. Although
the overall survival of patients with metastatic prostate cancer has improved with the addition …

5551 Background: Genomic characterization of mCRPC has identified commonly occurring
alterations but also recurrently mutated genes at much lower frequencies. To efficiently …

Discoveries of molecular mechanisms and therapeutic targets in metastatic castration-
resistant prostate cancer (CRPC) have led to significant advancements in the development …

The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is
undergoing significant changes with the advent of new therapies and multidisciplinary efforts …

Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading
cause of cancer-related deaths in US men in 2020. Androgen-deprivation therapy (ADT) is …

Ten years ago, the clinician treating metastatic castration-resistant prostate cancer (CRPC)
had palliative options for treatment of symptomatic patients, such as the combination of …

Radical prostatectomy and/or radiation therapy remain the main treatment modalities for
localized prostate cancer. However, biochemical recurrence (BCR; prostate-specific antigen …